This is the old version of SRDR. The next, SRDRplus is available! Registration of your SRDRPlus account is free and approval is automatic. Click Here to register an SRDRPlus account.

Advanced Search

Project: The Use of Chloroquine and Hydroxychloroquine for Prophylaxis and Treatment of COVID-19

Public Report Complete

Project Summary

Title and Description

Key Questions

Associated Extraction Forms

Title Created by Key Questions Addressed Form Notes
Extraction Form Bryant Smith 1

Associated Studies (each link opens a new tab)

Title Author Year
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial Chen Z, Hu J, Zhang Z, et al. 2020
Preliminary study of hydroxychloroquine sulfate in treating common coronavirus disease (COVID-19) patients in 2019 Chen J, Ping L, Li L , et al. 2020
Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial Tang W, Cao Z, Han M, et al. 2020
Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study) Borba MGS, Val FdA, Sampaio VS, et al. 2020
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents 2020 (in press) Gautret P, Lagier JC, Parola P, et al. 2020
Clinical Outcomes of Hydroxychloroquine in Hospitalized Patients with COVID-19: A Quasi- Randomized Comparative Study Barbosa J, Kaitis D, Freedman R, Le K, Lin X. 2020
No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial Mahévas M, Tran V-T, Roumier M, et al. 2020
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study Gautret P, Lagier J-C, Parola P, et al. 2020
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection Molina JM, Delaugerre C, Le Goff J, et al. 2020
Title Unavailable Raoult D. 2020
The QT Interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin Chorin E, Dai M, Shulman E, et al. 2020
Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit. Bessière F., Roccia H., Delinière A., Charrière R., Chevalier P., Argaud L., Cour M. 2020
Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring Ramireddy A, Chugh HS, Ebinger J, et al. 2020
QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin Chorin E, Wadhwani L, Magnani S, et al. 2020
The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection. Saleh M., Gabriels J., Chang D., Kim BS., Mansoor A., Mahmood E., Makker P., Ismail H., Goldner B., Willner J., Beldner S., Mitra R., John R., Chinitz J., Skipitaris N., Mountantonakis S., Epstein LM. 2020
Chloroquine-induced QTc prolongation in COVID-19 patients van den Broek, M.P.H., Möhlmann, J.E., Abeln, B.G.S. et al. 2020
Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 Magagnoli J, Narendran S, Pereira F, et al. 2020
Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19 Yu B, Wang DW, Li C. 2020
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). Mercuro NJ., Yen CF., Shim DJ., Maher TR., McCoy CM., Zimetbaum PJ., Gold HS. 2020
Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study Mallat J, Hamed F, Balkis M, et al. 2020
Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study. Membrillo de Novales, FJ, Ramírez-Olivencia, G, Estébanez, M, et al. 2020
Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19 Huang M, Li M, Xiao F, et al. 2020
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. Geleris J., Sun Y., Platt J., Zucker J., Baldwin M., Hripcsak G., Labella A., Manson D., Kubin C., Barr RG., Sobieszczyk ME., Schluger NW. 2020
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. Borba MGS., Val FFA., Sampaio VS., Alexandre MAA., Melo GC., Brito M., Mourão MPG., Brito-Sousa JD., Baía-da-Silva D., Guerra MVF., Hajjar LA., Pinto RC., Balieiro AAS., Pacheco AGF., Santos JDO., Naveca FG., Xavier MS., Siqueira AM., Schwarzbold A., Croda J., Nogueira ML., Romero GAS., Bassat Q., Fontes CJ., Albuquerque BC., Daniel-Ribeiro CT., Monteiro WM., Lacerda MVG. 2020

Creative Commons LicenseThis graphic notice indicates that you are leaving this Federal Government Web site and entering a non-Federal Web site. Creative Commons  
The data contained in this project are distributed under the terms of the Creative Commons Attribution-NonCommerical license, which permits the use, dissemination, and reproduction in any medium, provided the original work is properly cited, and that the use is non-commercial and otherwise in compliance with the license. See: